Chodakewitz Jeffrey 4

Accession 0001209191-23-046091

CIK 0001720580other

Filed

Aug 15, 8:00 PM ET

Accepted

Aug 16, 6:04 PM ET

Size

22.8 KB

Accession

0001209191-23-046091

Form 4

Period: 2023-08-14

Director

Transactions

Award
Stock Option (Right to Buy)
2023-08-14+26,400→ 26,400 total
Exercise: $2.14Exp: 2033-05-31→ Common Stock (26,400 underlying)
Disposition to Issuer
Stock Option (Right to Buy)
2023-08-14−18,500→ 0 total
Exercise: $15.93Exp: 2031-04-29→ Common Stock (18,500 underlying)
Award
Stock Option (Right to Buy)
2023-08-14+18,500→ 18,500 total
Exercise: $2.14Exp: 2031-04-29→ Common Stock (18,500 underlying)
Disposition to Issuer
Stock Option (Right to Buy)
2023-08-14−30,000→ 0 total
Exercise: $16.11Exp: 2030-09-16→ Common Stock (30,000 underlying)
Award
Stock Option (Right to Buy)
2023-08-14+30,000→ 30,000 total
Exercise: $2.14Exp: 2030-09-16→ Common Stock (30,000 underlying)
Disposition to Issuer
Stock Option (Right to Buy)
2023-08-14−18,500→ 0 total
Exercise: $11.49Exp: 2032-06-01→ Common Stock (18,500 underlying)
Award
Stock Option (Right to Buy)
2023-08-14+18,500→ 18,500 total
Exercise: $2.14Exp: 2032-06-01→ Common Stock (18,500 underlying)
Disposition to Issuer
Stock Option (Right to Buy)
2023-08-14−26,400→ 0 total
Exercise: $5.20Exp: 2033-05-31→ Common Stock (26,400 underlying)

Footnotes (5)

[F1]On August 8, 2023, the Issuer's Board of Directors approved an option repricing (the "Repricing"), effective as of August 14, 2023 (the "Effective Date"). All of the other terms of the options remain unchanged. Such transactions were exempt pursuant to Rule 16b-6(d) and Rule 16b-3 of the Exchange Act, as applicable.
[F2]The shares subject to this option shall vest in thirty-six (36) equal monthly installments commencing on September 17, 2020, subject to the Reporting Person's continued service on the Issuer's Board of Directors as of the applicable vesting date.
[F3]The exercise price of the option is $2.14 per share, representing the fair market value per share of the Issuer's Common Stock on the Effective Date; provided that the repriced option will revert to its original exercise price if, prior to the first anniversary of the Effective Date, (a) the Reporting Person's service on the Issuer's Board of Directors is terminated by the Issuer with cause or by the Reporting Person or (b) the option is exercised.
[F4]The shares subject to this option are fully vested and exercisable as of the date hereof.
[F5]The shares subject to this option shall vest in full on the earlier to occur of (a) June 1, 2024 or (b) the date of the Issuer's 2024 annual meeting of stockholders, subject to the Reporting Person's continued service on the Issuer's Board of Directors as of the applicable vesting date.

Documents

1 file

Adicet Bio, Inc.

CIK 0001720580

Entity typeother